FibroGen Inc (FGEN) – Strategy, SWOT and Corporate Finance Report
- Pages: 49
- Published: May 2023
- Report Code: MLPH13844FSA
FibroGen Inc (FGEN) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company
Key Highlights
FibroGen Inc (FibroGen) is a biopharmaceutical company that discovers, and develops medicines for the treatment of anemia, cancer, and fibrotic disease. Its approved product includes roxadustat for the treatment of treatment of anemia associated with chronic kidney disease, in both dialysis-dependent (DD) and non-dialysis-dependent (NDD) patients. Its pipeline product includes pamrevlumab (FG-3019) for the treatment of idiopathic pulmonary fibrosis (IPF) and duchenne muscular dystrophy (DMD). The company has operations in the US, Hong Kong, Finland, Cayman Islands and China. FibroGen is headquartered in San Francisco, California, the US.
Scope
• Detailed information on FibroGen Inc required for business and competitor intelligence needs
• A study of the major internal and external factors affecting FibroGen Inc in the form of a SWOT analysis
• An in-depth view of the business model of FibroGen Inc including a breakdown and examination of key business segments
• News about FibroGen Inc, such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
• Gain understanding of FibroGen Inc and the factors that influence its strategies.• Track strategic initiatives of the company and latest corporate news and actions.
• Assess FibroGen Inc as a prospective partner, vendor or supplier.
• Support sales activities by understanding your customers' businesses better.
• Stay up to date on FibroGen Incs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
Vifor Pharma Management Ltd
Sandoz Inc
Pfizer Inc
Kyowa Kirin Co Ltd
Johnson & Johnson
GSK plc
Glycomantra Inc
F. Hoffmann-La Roche Ltd
Celgene Corp
Boehringer Ingelheim International GmbH
Bayer AG
Amgen Inc
Akebia Therapeutics Inc
Acceleron Pharma Inc
3SBio Inc
F. Hoffmann-La Roche Ltd
Bayer AG
3SBio Inc
Akebia Therapeutics Inc
Johnson & Johnson
Boehringer Ingelheim International GmbH
Glycomantra Inc
Kyowa Kirin Co Ltd
Pfizer Inc
GSK plc
Vifor Pharma Ltd
Celgene Corp
Sandoz Inc
Acceleron Pharma Inc
Amgen Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.